Login to Your Account



Therapeuticsmd faces down FDA complete response

By Michael Fitzhugh
Staff Writer

Monday, May 8, 2017

A lack of 12-month endometrial safety data led to the FDA's rejection of an NDA filed by Therapeuticsmd Inc. for Yuvvexy, an investigational treatment of moderate to severe vaginal pain during sex.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription